Are you over 18 and want to see adult content?
More Annotations
A complete backup of longchamppas-cher.fr
Are you over 18 and want to see adult content?
A complete backup of nbajerseyoriginal.com
Are you over 18 and want to see adult content?
A complete backup of grundeinkommen.de
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of perfectgirls.net
Are you over 18 and want to see adult content?
A complete backup of www.kaufmich.com
Are you over 18 and want to see adult content?
A complete backup of www.redlights.be
Are you over 18 and want to see adult content?
A complete backup of www.naturistscans.com
Are you over 18 and want to see adult content?
A complete backup of www.quartier-rouge.be
Are you over 18 and want to see adult content?
A complete backup of playforceone.com
Are you over 18 and want to see adult content?
A complete backup of naughtyamericavip.com
Are you over 18 and want to see adult content?
A complete backup of www.czechspy.com
Are you over 18 and want to see adult content?
A complete backup of arabicfemdom.com
Are you over 18 and want to see adult content?
Text
CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. CLINICAL VERSION: CANADIAN TIA SCORE Estimate 7-day Risk of Stroke or Carotid Revascularization. The Canadian Transient Ischaemic Score is decision tool stratifies patients’ seven day risk for stroke, with or without carotid endarterectomy/carotid artery stenting, after presenting to the emergency department with a transient ischemic attack.PHASES SCORE
The PHASES score is an aid for prediction of the risk of rupture for asymptomatic intracranial aneurysms. The score is based on a systematical review of six prospective cohort studies with subarachnoid hemorrhage as outcome. 8382 participants in the USA, Europe and Japan were included.BASDAI | QXMD
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) disease activity questionnaire contains six questions regarding subjective symptoms during the week prior to answering the questions.MGUS PROGNOSIS
Determine risk of malignant progression to myleoma or lymphoproliferative disorder. Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS. FINDRISC DIABETES RISK CALCULATOR FINDRISC is a prediction tool to identify patients at risk of developing diabetes. It requires no laboratory testing and has been validated in multiple populations. PRE-TEST PROBABILITY OF CAD (CAD CONSORTIUM) This calculator was developed and validated based on more than 5500 patients from 18 different hospitals across Europe and the United States (1), a collaborative effort of the CAD consortium. CNS INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies. MALT LYMPHOMA PROGNOSIS (MALT-IPI) Estimate prognosis in MALT lymphoma. The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil,rituximab, or both.
QXMD | MOVING RESEARCH INTO PRACTICE | QXMDREAD BY QXMDCALCULATE BY QXMDLEARN BY QXMDRESEARCH DISSEMINATIONINTERACTIVE TOOLS For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available.CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. CLINICAL VERSION: CANADIAN TIA SCORE Estimate 7-day Risk of Stroke or Carotid Revascularization. The Canadian Transient Ischaemic Score is decision tool stratifies patients’ seven day risk for stroke, with or without carotid endarterectomy/carotid artery stenting, after presenting to the emergency department with a transient ischemic attack.PHASES SCORE
The PHASES score is an aid for prediction of the risk of rupture for asymptomatic intracranial aneurysms. The score is based on a systematical review of six prospective cohort studies with subarachnoid hemorrhage as outcome. 8382 participants in the USA, Europe and Japan were included.BASDAI | QXMD
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) disease activity questionnaire contains six questions regarding subjective symptoms during the week prior to answering the questions.MGUS PROGNOSIS
Determine risk of malignant progression to myleoma or lymphoproliferative disorder. Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS. FINDRISC DIABETES RISK CALCULATOR FINDRISC is a prediction tool to identify patients at risk of developing diabetes. It requires no laboratory testing and has been validated in multiple populations. PRE-TEST PROBABILITY OF CAD (CAD CONSORTIUM) This calculator was developed and validated based on more than 5500 patients from 18 different hospitals across Europe and the United States (1), a collaborative effort of the CAD consortium. CNS INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies. MALT LYMPHOMA PROGNOSIS (MALT-IPI) Estimate prognosis in MALT lymphoma. The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil,rituximab, or both.
QXMD | MOVING RESEARCH INTO PRACTICE | QXMD For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available. FINDRISC DIABETES RISK CALCULATOR FINDRISC is a prediction tool to identify patients at risk of developing diabetes. It requires no laboratory testing and has been validated in multiple populations. CLINICAL VERSION: EGFR USING CKD-EPI The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation was developed in an effort to create a more precise formula to estimate glomerular filtrate rate (GFR) from serum creatinine and other readily available clinical parameters, especially at when actual GFR is >60 mL/min per 1.73m 2.. Researchers pooled data from multiple studies to develop and validate this new equation. SHUNT FRACTION (INVASIVE) *If a pulmonary vein has not been entered the arterial saturation (SAO2) may be substituted, provided that there is no right to left shunt. The magnitude of an inra- or extracardiac shunt can be estimated by flow ratio between the pulmonary and systemic circulation (Qp/Qs) using hemodynamic data. CLINICAL VERSION: KIDNEY FAILURE RISK EQUATION The kidney failure risk equations were developed in patients with CKD stages G3-G5 referred to nephrologists in Canada, and have now been validated in more than 700,000 individuals spanning 30 + countriesworldwide.
MULTIPLE MYELOMA PROGNOSIS (R-ISS) The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification. PROGNOSIS IN HODGKIN'S DISEASE The Hasenclever International Prognostic Score (IPS) was designed to predict five-year freedom from progression of Hodgkin's disease. With each additional adverse prognostic factor, the predicted rate is reduced by approximately 8%. IMMUNE THROMBOCYTOPENIA AND COVID-19: CASE REPORT AND Immune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), has been reported as an important complication related to COVID-19.We present a 49-year-old male patient with systemic lupus erythematosus with lupus nephritis, antiphospholipid syndrome and history of ITP who developed an ITP flare in the context of COVID-19. He had no bleeding manifestations and had a good response MALT LYMPHOMA PROGNOSIS (MALT-IPI) Estimate prognosis in MALT lymphoma. The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil,rituximab, or both.
ADMISSIONS FOR AND QUALITY OF CARE OF ST-SEGMENT-ELEVATION OBJECTIVE: To evaluate changes in admission rates for and quality of care of ST-Segment-Elevation Myocardial Infarction (STEMI) during the period of the coronavirus disease 2019 (COVID-19) outbreak and post COVID-19 era. METHODS: We conducted a retrospective cohort study of patients with STEMI in the outbreak era (between January 23, 2020 and March 27, 2020), and the post era (between March 28 QXMD | MOVING RESEARCH INTO PRACTICE | QXMDREAD BY QXMDCALCULATE BY QXMDLEARN BY QXMDRESEARCH DISSEMINATIONINTERACTIVE TOOLS For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available.CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. CLINICAL VERSION: CANADIAN TIA SCORE Estimate 7-day Risk of Stroke or Carotid Revascularization. The Canadian Transient Ischaemic Score is decision tool stratifies patients’ seven day risk for stroke, with or without carotid endarterectomy/carotid artery stenting, after presenting to the emergency department with a transient ischemic attack.PHASES SCORE
The PHASES score is an aid for prediction of the risk of rupture for asymptomatic intracranial aneurysms. The score is based on a systematical review of six prospective cohort studies with subarachnoid hemorrhage as outcome. 8382 participants in the USA, Europe and Japan were included.BASDAI | QXMD
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) disease activity questionnaire contains six questions regarding subjective symptoms during the week prior to answering the questions.MGUS PROGNOSIS
Determine risk of malignant progression to myleoma or lymphoproliferative disorder. Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS. FINDRISC DIABETES RISK CALCULATOR FINDRISC is a prediction tool to identify patients at risk of developing diabetes. It requires no laboratory testing and has been validated in multiple populations. PRE-TEST PROBABILITY OF CAD (CAD CONSORTIUM) This calculator was developed and validated based on more than 5500 patients from 18 different hospitals across Europe and the United States (1), a collaborative effort of the CAD consortium. CNS INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies. MALT LYMPHOMA PROGNOSIS (MALT-IPI) Estimate prognosis in MALT lymphoma. The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil,rituximab, or both.
QXMD | MOVING RESEARCH INTO PRACTICE | QXMDREAD BY QXMDCALCULATE BY QXMDLEARN BY QXMDRESEARCH DISSEMINATIONINTERACTIVE TOOLS For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available.CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. CLINICAL VERSION: CANADIAN TIA SCORE Estimate 7-day Risk of Stroke or Carotid Revascularization. The Canadian Transient Ischaemic Score is decision tool stratifies patients’ seven day risk for stroke, with or without carotid endarterectomy/carotid artery stenting, after presenting to the emergency department with a transient ischemic attack.PHASES SCORE
The PHASES score is an aid for prediction of the risk of rupture for asymptomatic intracranial aneurysms. The score is based on a systematical review of six prospective cohort studies with subarachnoid hemorrhage as outcome. 8382 participants in the USA, Europe and Japan were included.BASDAI | QXMD
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) disease activity questionnaire contains six questions regarding subjective symptoms during the week prior to answering the questions.MGUS PROGNOSIS
Determine risk of malignant progression to myleoma or lymphoproliferative disorder. Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS. FINDRISC DIABETES RISK CALCULATOR FINDRISC is a prediction tool to identify patients at risk of developing diabetes. It requires no laboratory testing and has been validated in multiple populations. PRE-TEST PROBABILITY OF CAD (CAD CONSORTIUM) This calculator was developed and validated based on more than 5500 patients from 18 different hospitals across Europe and the United States (1), a collaborative effort of the CAD consortium. CNS INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies. MALT LYMPHOMA PROGNOSIS (MALT-IPI) Estimate prognosis in MALT lymphoma. The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil,rituximab, or both.
QXMD | MOVING RESEARCH INTO PRACTICE | QXMD For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available. FINDRISC DIABETES RISK CALCULATOR FINDRISC is a prediction tool to identify patients at risk of developing diabetes. It requires no laboratory testing and has been validated in multiple populations. CLINICAL VERSION: EGFR USING CKD-EPI The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation was developed in an effort to create a more precise formula to estimate glomerular filtrate rate (GFR) from serum creatinine and other readily available clinical parameters, especially at when actual GFR is >60 mL/min per 1.73m 2.. Researchers pooled data from multiple studies to develop and validate this new equation. SHUNT FRACTION (INVASIVE) *If a pulmonary vein has not been entered the arterial saturation (SAO2) may be substituted, provided that there is no right to left shunt. The magnitude of an inra- or extracardiac shunt can be estimated by flow ratio between the pulmonary and systemic circulation (Qp/Qs) using hemodynamic data. CLINICAL VERSION: KIDNEY FAILURE RISK EQUATION The kidney failure risk equations were developed in patients with CKD stages G3-G5 referred to nephrologists in Canada, and have now been validated in more than 700,000 individuals spanning 30 + countriesworldwide.
MULTIPLE MYELOMA PROGNOSIS (R-ISS) The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification. PROGNOSIS IN HODGKIN'S DISEASE The Hasenclever International Prognostic Score (IPS) was designed to predict five-year freedom from progression of Hodgkin's disease. With each additional adverse prognostic factor, the predicted rate is reduced by approximately 8%. IMMUNE THROMBOCYTOPENIA AND COVID-19: CASE REPORT AND Immune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), has been reported as an important complication related to COVID-19.We present a 49-year-old male patient with systemic lupus erythematosus with lupus nephritis, antiphospholipid syndrome and history of ITP who developed an ITP flare in the context of COVID-19. He had no bleeding manifestations and had a good response MALT LYMPHOMA PROGNOSIS (MALT-IPI) Estimate prognosis in MALT lymphoma. The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil,rituximab, or both.
ADMISSIONS FOR AND QUALITY OF CARE OF ST-SEGMENT-ELEVATION OBJECTIVE: To evaluate changes in admission rates for and quality of care of ST-Segment-Elevation Myocardial Infarction (STEMI) during the period of the coronavirus disease 2019 (COVID-19) outbreak and post COVID-19 era. METHODS: We conducted a retrospective cohort study of patients with STEMI in the outbreak era (between January 23, 2020 and March 27, 2020), and the post era (between March 28 QXMD | MOVING RESEARCH INTO PRACTICE | QXMDREAD BY QXMDCALCULATE BY QXMDLEARN BY QXMDRESEARCH DISSEMINATIONINTERACTIVE TOOLS For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available.CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool.PHASES SCORE
The PHASES score is an aid for prediction of the risk of rupture for asymptomatic intracranial aneurysms. The score is based on a systematical review of six prospective cohort studies with subarachnoid hemorrhage as outcome. 8382 participants in the USA, Europe and Japan were included. CLINICAL VERSION: CANADIAN TIA SCORE Estimate 7-day Risk of Stroke or Carotid Revascularization. The Canadian Transient Ischaemic Score is decision tool stratifies patients’ seven day risk for stroke, with or without carotid endarterectomy/carotid artery stenting, after presenting to the emergency department with a transient ischemic attack.MGUS PROGNOSIS
Determine risk of malignant progression to myleoma or lymphoproliferative disorder. Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS.BASDAI | QXMD
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) disease activity questionnaire contains six questions regarding subjective symptoms during the week prior to answering the questions. CLINICAL VERSION: SPINAL INSTABILITY NEOPLASTIC SCORE The spinal instability neoplastic score (SINS) helps to assess tumor related instability of the vertebral column. It has been shown to useful in guiding the mobilization or operative management of patients with neoplastic spinal disease. MULTIPLE MYELOMA PROGNOSIS (R-ISS) The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification. CNS INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies. GLOMERULOSCLEROSIS ON BIOPSY (2015) Differentiate glomerulosclerosis from kidney disease vs from aging. The glomerulosclerosis prediction tool was developed using the implantation biopsies of 1847 normotensive living kidney donors from Mayo Clinic (Minnesota and Arizona sites) and Cleveland Clinic. QXMD | MOVING RESEARCH INTO PRACTICE | QXMDREAD BY QXMDCALCULATE BY QXMDLEARN BY QXMDRESEARCH DISSEMINATIONINTERACTIVE TOOLS For Conference Organizers. Grow attendance for your next medical event or conference. No risk, no minimum commitment. Connect with a highly-engaged, almost 2-million strong community on the QxMD platform. Learn More. Decision Support Tools Available.CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool.PHASES SCORE
The PHASES score is an aid for prediction of the risk of rupture for asymptomatic intracranial aneurysms. The score is based on a systematical review of six prospective cohort studies with subarachnoid hemorrhage as outcome. 8382 participants in the USA, Europe and Japan were included. CLINICAL VERSION: CANADIAN TIA SCORE Estimate 7-day Risk of Stroke or Carotid Revascularization. The Canadian Transient Ischaemic Score is decision tool stratifies patients’ seven day risk for stroke, with or without carotid endarterectomy/carotid artery stenting, after presenting to the emergency department with a transient ischemic attack.MGUS PROGNOSIS
Determine risk of malignant progression to myleoma or lymphoproliferative disorder. Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS.BASDAI | QXMD
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) disease activity questionnaire contains six questions regarding subjective symptoms during the week prior to answering the questions. CLINICAL VERSION: SPINAL INSTABILITY NEOPLASTIC SCORE The spinal instability neoplastic score (SINS) helps to assess tumor related instability of the vertebral column. It has been shown to useful in guiding the mobilization or operative management of patients with neoplastic spinal disease. MULTIPLE MYELOMA PROGNOSIS (R-ISS) The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification. CNS INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies. GLOMERULOSCLEROSIS ON BIOPSY (2015) Differentiate glomerulosclerosis from kidney disease vs from aging. The glomerulosclerosis prediction tool was developed using the implantation biopsies of 1847 normotensive living kidney donors from Mayo Clinic (Minnesota and Arizona sites) and Cleveland Clinic.FEATURED PAPERS
Read by QxMD helps you keep up-to-date with groundbreaking research in your area of practice. Leverage your existing university affiliation and subscription to get one-touch access to thousands of premium PDF articles from high-impact journals like the New England Journal of Medicine and the Lancet right on your iPad, iPhone, Android and web-enabled desktop.READ BY QXMD
Read by QxMD helps you keep up-to-date with groundbreaking research in your area of practice. Leverage your existing university affiliation and subscription to get one-touch access to thousands of premium PDF articles from high-impact journals like the New England Journal of Medicine and the Lancet right on your iPad, iPhone, Android and web-enabled desktop.CMML CPSS-MOL
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. STRUCTURAL DYNAMICS OF SARS-COV-2 VARIANTS: A HEALTH OBJECTIVES: The Covid-19 pandemic has been marked by sudden outbreaks of SARS-CoV-2 variants harboring mutations in both the N-terminal (NTD) and receptor binding (RBD) domains of the spike protein. The goal of this study was to predict the transmissibility of SARS-CoV-2 variants from genomic sequence data. METHODS: We used a target-based molecular modeling strategy combined with MULTIPLE MYELOMA PROGNOSIS (R-ISS) The Revised International Staging System (R-ISS) includes variables included in the original ISS (serum beta-2 microglobulin and serum albumin), while also including the additional prognostic information obtained from serum LDH and high-risk chromosomal abnormalities detected by interphase fluorescent in situ hybridization (iFISH) after CD138 plasma cell purification. PULMONARY RESISTANCE TPR reflects the resistance to diastolic flow across the pulmonary circulation from PA to LV, neglecting LV diastolic pressure. TPR is easily influenced by alterations in LA pressure, and as such does not always reflect pulmonary vasculature. PROGNOSIS IN HODGKIN'S DISEASE The Hasenclever International Prognostic Score (IPS) was designed to predict five-year freedom from progression of Hodgkin's disease. With each additional adverse prognostic factor, the predicted rate is reduced by approximately 8%. EXPECTED SPLEEN SIZE Spleen size is significantly influenced by body height and sex. This tool is designed to calculate approximate percentiles of an individual´s spleen size. NEWBORN HYPERBILIRUBINEMIA RATE OF RISE 60% of term infants and 80% of preterm newborns develop jaundice, a condition characterized by yellowing of the skin or whites of the eyes, arising from elevated serum bilirubin levels. EFFECTIVE DNA DAMAGE RESPONSE AFTER ACUTE BUT NOT CHRONIC Whether and how an acute immune challenge may affect DNA Damage Response (DDR) is unknown. By studying vaccinations against Influenza and SARS-CoV-2 (mRNA-based) we found acute increases of type-I interferon-inducible gene expression, oxidative stress and DNA damage accumulation in blood mononuclear cells of 9 healthy controls, coupled with effective anti-SARS-CoV-2 neutralizing antibody* Apps
* Read by QxMD
* Calculate by QxMD
* Learn by QxMD
* Solutions
* Research Dissemination* Interactive Tools
* Guideline Digitization * Conference Promotion * Services for Medical Journals * Read, Institutional Edition * Continuing Medical Education * Features for Developers* Contact
* General Enquiries
* Tech Support
* Corporate Sales
Select Page
* Apps
* Read by QxMD
* Calculate by QxMD
* Learn by QxMD
* Solutions
* Research Dissemination* Interactive Tools
* Guideline Digitization * Conference Promotion * Services for Medical Journals * Read, Institutional Edition * Continuing Medical Education * Features for Developers* Contact
* General Enquiries
* Tech Support
* Corporate Sales
BETTER DECISIONS AT THE POINT OF CARE Mobile solutions that drive evidence-based medicine in clinicalpractice.
Contact UsLearn More3
BETTER DECISIONS AT THE POINT OF CARE Mobile solutions that drive evidence-based medicine in clinicalpractice.
Contact Us
3
FOR HEALTHCARE PROFESSIONALS APPS TO KEEP UP WITH THE LATEST RESEARCH AND INTEGRATE DECISION SUPPORT TOOLS INTO PRACTICEREAD BY QXMD
READ BY QXMD HELPS YOU STAY ON TOP OF THE MOST IMPORTANT AND CUTTING-EDGE RESEARCHLearn More
CALCULATE BY QXMD
CALCULATE BY QXMD OFFERS >400 POINT-OF-CARE TOOLS TO EDUCATE AROUND PROGNOSIS, DIAGNOSIS AND OPTIMAL PATIENT MANAGEMENTLearn More
FOR ORGANIZATIONS
DISSEMINATE RESEARCH TO FRONT LINE CLINICIANS IN ORDER TO DRIVE PRACTICE CHANGE & IMPROVE HEALTHCARE QUALITY METRICS
TRY READ, INSTITUTIONAL EDITION TO MAXIMIZE VALUE FROM YOUR DIGITAL JOURNAL SUBSCRIPTIONS.
CONVERT MEDICAL EVIDENCE, GUIDELINES AND PROTOCOLS INTO PRACTICAL TOOLS YOUR CLINICIANS WILL LOVE TO USELearn More
Get Started Today
Learn More
DISSEMINATE RESEARCH TO FRONT LINE CLINICIANS IN ORDER TO DRIVE PRACTICE CHANGE & IMPROVE HEALTHCARE QUALITY METRICSLearn More
TRY READ, INSTITUTIONAL EDITION TO MAXIMIZE VALUE FROM YOUR DIGITAL JOURNAL SUBSCRIPTIONS.Get Started Today
CONVERT MEDICAL EVIDENCE, GUIDELINES AND PROTOCOLS INTO PRACTICAL TOOLS YOUR CLINICIANS WILL LOVE TO USELearn More
FOR RESEARCHERS
COLLABORATE WITH QXMD TO MAKE YOUR CLINICAL RESEARCH INSTANTLY AVAILABLE IN THE HANDS OF >1 MILLION PRACTICING HEALTHCARE PROVIDERSLearn More
FOR RESEARCHERS
COLLABORATE WITH QXMD TO MAKE YOUR CLINICAL RESEARCH INSTANTLY AVAILABLE IN THE HANDS OF >1 MILLION PRACTICING HEALTHCARE PROVIDERSLearn More
FOR GUIDELINE DEVELOPERS WE SOLVE KNOWLEDGE TRANSLATION BY ADAPTING YOUR WORK INTO AN INTERACTIVE DIGITAL TOOL AND DRIVING ENGAGEMENT WITH YOUR TARGETCLINICAL AUDIENCE.
Learn More
FOR MEDICAL & SCIENTIFIC JOURNALS*
INCREASE READERSHIP BY DISSEMINATING GUIDELINES & NEW RESEARCH TO YOURTARGET AUDIENCE.
*
ADAPT PROGNOSTIC MODELS INTO POINT OF CARE, DIGITAL DECISION SUPPORTTOOLS
*
HELP READERS ENGAGE WITH PUBLISHED CONTENTLearn More
FOR CONFERENCE ORGANIZERS*
GROW ATTENDANCE FOR YOUR NEXT MEDICAL EVENT OR CONFERENCE*
NO RISK, NO MINIMUM COMMITMENT*
CONNECT WITH A HIGHLY-ENGAGED, ALMOST 2-MILLION STRONG COMMUNITY ONTHE QXMD PLATFORM
Learn More
FOR CONFERENCE ORGANIZERS*
GROW ATTENDANCE FOR YOUR NEXT MEDICAL EVENT OR CONFERENCE*
NO RISK, NO MINIMUM COMMITMENT*
CONNECT WITH A HIGHLY-ENGAGED, ALMOST 2-MILLION STRONG COMMUNITY ONTHE QXMD PLATFORM
Learn More
DECISION SUPPORT TOOLS AVAILABLE MILLION RESEARCH CITATIONS READ MILLION QXMD USERS PER YEAR NUMBER OF PATIENTS WE NEED TO HELP TO MAKE IT ALL WORTH IT AT QXMD, WE WORK WITH RESEARCHERS, HOSPITALS, UNIVERSITIES, NON-PROFITS & OTHERS TO DISSEMINATE PUBLICATIONS & ADAPT CLINICAL RESEARCH INTO SIMPLE TO USE TOOLS. OUR GOAL IS ADOPTION OF PRACTICE CHANGING RESEARCH AT THE POINT OFCARE.
HOW CAN WE HELP YOU?Name
Email Address
Phone (optional)
Message
Get in Touch
OUR SOFTWARE
ABOUT READ
Read for iOS
Read for Android
Read for Web
Read for WordPress
ABOUT CALCULATE
Calculate for iOS
Calculate for AndroidCalculate for Web
ABOUT PEDI STAT
Pedi STAT for iOS
Pedi STAT for AndroidOUR SOLUTIONS
Research DisseminationInteractive Tools
Guideline Digitization Solutions for Medical Journals Conference Promotion Read, Institutional Edition Continuing Medical Education Features for DevelopersOUR COMPANY
Contact Us
Blog
Support
Cookie Policy
Privacy Policy
Terms of Use
Curator Program
Team
News
Allow All
MANAGE COOKIE PREFERENCES STRICTLY NECESSARY COOKIESAlways Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information. SALE OF PERSONAL DATAAlways Active
Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link. If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according toyour preferences.
*
PERFORMANCE COOKIES
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.*
TARGETING COOKIES
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.Confirm My Choices
Back Button
Back
PERFORMANCE COOKIES
Vendor Search Search Icon Filter IconClear Fliters
Information storage and accessApplyAll Consent Allowed
Select All Vendors
All Consent Allowed
*
33ACROSS
HOST DESCRIPTION
VIEW COOKIES
REPLACE-WITH-DYANMIC-HOST-ID*
Name
cookie name
Host
cookie host
Duration
cookie duration
Type
cookie type
Category
cookie category
Description
cookie category
*
33ACROSS
View Privacy Notice
3 Purposes
REPLACE-WITH-DYANMIC-VENDOR-IDArrow
Consent Purposes
Location Based Ads
Consent Allowed
Legitimate Interest PurposesPersonalize
Require Opt-Out
Features
Location Based Ads
Confirm My Choices
This website uses cookies to collect information and analytics about how you interact with our website and potentially to deliver custom promoted content. Learn more here.Ok
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0